Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Use of Ointments in Prevention of Catheter Related Infections in PD

This study has been completed.
Information provided by (Responsible Party):
Vanita Jassal, University Health Network, Toronto Identifier:
First received: November 15, 2006
Last updated: March 16, 2015
Last verified: March 2015
Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in approximately 25% of patients requiring dialysis in Canada. The most common complication is bacterial infection or 'peritonitis'. Peritonitis causes severe acute abdominal pain and may lead to failure of peritoneal dialysis treatment, hospitalization or death, particularly if left untreated. Amongst the strategies used to prevent peritonitis, patients are instructed on the regular use of a prophylactic ointment around the point where the catheter exits from the body. At the present time most centers in Canada routinely prescribe mupirocin ointment for use at the exit site, however newer ointments have become available. One such ointment is Polysporin Triple. The aim of this study is to determine if catheter related infections can be significantly reduced by the routine application of Polysporin Triple in comparison to mupirocin ointment. A multi-centre, randomized, double blind, controlled study is proposed. Participants will be randomized to either mupirocin or Polysporin Triple and followed for 18 months or until the first catheter related infection, death or catheter removal. The difference in catheter related infection rates will be compared between the two groups. We anticipate the results of this study will allow clinicians to prescribe the ointment most likely to reduce infections. By doing so this will reduce the complication rate associated with peritoneal dialysis and, ultimately improve survival.

Condition Intervention Phase
End Stage Renal Disease
Drug: Mupirocin ointment
Drug: Polysporin Triple
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-related Infections in Patients Treated With Peritoneal Dialysis

Resource links provided by NLM:

Further study details as provided by Vanita Jassal, University Health Network, Toronto:

Primary Outcome Measures:
  • The primary endpoint is the time to first catheter related infection. [ Time Frame: 2Yrs ]

Secondary Outcome Measures:
  • Removal of the catheter to prevent or halt progression of a catheter related infection [ Time Frame: 2 yrs ]
  • Hospitalizations related to catheter related infection [ Time Frame: 2 yrs ]
  • Death due to catheter-related infection [ Time Frame: 2 yrs ]
  • All-cause mortality [ Time Frame: 2yrs ]
  • Technique failure (i.e. transfer to hemodialysis) [ Time Frame: 2yrs ]
  • Mupirocin or Polysporin Triple resistance [ Time Frame: 2yrs ]

Enrollment: 200
Study Start Date: February 2006
Study Completion Date: June 2010
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
Drug: Polysporin Triple
Active Comparator: 2
Drug: Mupirocin ointment
topical ointment (already in widespread clinical use)

Detailed Description:
Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in approximately 25% of patients requiring dialysis in Canada. The most common PD related complication is infective peritonitis, a syndrome of acute pain, cloudy peritoneal dialysate, and infection. Although many cases of peritonitis can be treated as an outpatient, recurrent or unresolving infections can result in fibrotic changes in the peritoneal membrane, catheter removal or patient death. Gram positive organisms are amongst the commonest causes of PD peritonitis; however, recent trends show an increasing rate of gram negative and fungal infections. Strategies to prevent peritonitis include the use of prophylactic topical mupirocin at the site where the PD catheter exits from the abdominal wall. Despite this and other innovations peritonitis is still diagnosed, on average, in one patient out of every 24 patients followed for a month. The aim of this study is to determine if the incidence of catheter related infections (exit site infection, tunnel infection or peritonitis) is significantly reduced by the routine application of Polysporin Triple in comparison to mupirocin ointment.A multi-centre randomized double blind, controlled study is proposed. Polysporin Triple will be compared against the current standard of care. All patients currently being treated with, or starting onto, peritoneal dialysis will be eligible. Participants will be randomized to one of two treatment arms (mupirocin; Polysporin Triple) and stratified according to a) centre b) vintage (incident versus prevalent), and c) type of PD (chronic ambulatory peritoneal dialysis vs. automated PD). Patients will be followed for 18 months or until the first catheter related infection, death or catheter removal due to technique failure. Catheter related infections will be strictly defined using current guidelines and categorized into exit site infections, infective peritonitis or tunnel infections.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able and willing to provide informed consent*
  2. Age over 18 years
  3. Has a peritoneal dialysis catheter in situ and

    • Is established on PD for more than 3 months (prevalent patients)
    • Is undergoing training for or has initiated PD within the last 3 months (incident patients)
  4. Medically stable (as defined by primary nephrologist)
  5. Regularly applying mupirocin ointment to catheter exit site

Exclusion Criteria:

  1. Presence of acute renal failure
  2. Catheter related infection at the time of recruitment or within the previous 3 months
  3. Use of an oral or IV antibiotic at the time of randomization or within the previous 1 week.
  4. Known allergy to any component of gentamicin or mupirocin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00400595

Canada, Ontario
Scarborough General Hospital
Toronto, Ontario, Canada, M1P 2V5
University Health Network
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Vanita Jassal, MD University Health Network, Toronto
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Vanita Jassal, Principal Investigator, University Health Network, Toronto Identifier: NCT00400595     History of Changes
Other Study ID Numbers: 05-0850-AE
Study First Received: November 15, 2006
Last Updated: March 16, 2015

Keywords provided by Vanita Jassal, University Health Network, Toronto:
catheter related infection
exit site ointments
Polysporin Triple

Additional relevant MeSH terms:
Kidney Failure, Chronic
Catheter-Related Infections
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Polymyxin B
Anti-Infective Agents, Local
Anti-Infective Agents
Anti-Bacterial Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017